Dynavax Technologies Corp (DVAX): Eddie Gray , CEO of Dynavax Technologies Corp purchased 2,750 shares on May 20, 2016. The Insider buying transaction was reported by the company on May 23, 2016 to the Securities and Exchange Commission. The shares were purchased at $15.57 per share for a total value of $42,819.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 13, 2016, Robert Janssen (Vice President) purchased 1,000 shares at $15.12 per share price.
Dynavax Technologies Corporation: On Friday, May 20, 2016 heightened volatility was witnessed in Dynavax Technologies Corporation which led to swings in the share price. The shares opened for trading at $15.36 and hit $15.76 on the upside , eventually ending the session at $15.71, with a gain of 3.29% or 0.5 points. The heightened volatility saw the trading volume jump to 5,03,233 shares. The 52-week high of the share price is $32.49 and the company has a market cap of $604,772 M . The 52-week low of the share price is at $13.58.
Company has been under the radar of several Street Analysts.Dynavax Technologies Corporation is Downgraded by RBC Capital Mkts to Sector Perform while Lowering the Price Target of the company shares to $ 17 from a previous price target of $48 . Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Apr 28, 2016.Dynavax Technologies Corporation is Downgraded by JP Morgan to Neutral. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Apr 27, 2016.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants cancer immunotherapy and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B an investigational adult hepatitis B vaccine is in Phase III clinical trials; SD-101 a cancer immunotherapy candidate is in Phase I/II clinical trials; AZD1419 a candidate drug for asthma is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.